MicroGeneSys Inc. on Thursday announced that a Phase IIIclinical trial of its HIV/AIDS therapeutic vaccine, gp160, hasbegun in Sweden.
The trial, involving 1,000 HIV-infected patients, will be led byresearchers from the Karolinska Institute, the NationalBacteriological Laboratory and South Hospital in Stockholm, theMeriden, Conn., company said. Enrollment of patients inDenmark, Norway and Finland is expected as the trialprogresses.
Prior human clinicals have shown gp160 to be safe for use inhumans and that it stimulates both antibody and cellularimmune responses agianst HIV, the company said.020593GP160
(c) 1997 American Health Consultants. All rights reserved.